Law360, New York (January 15, 2014, 8:40 PM EST) -- The first installment of U.S. Food and Drug Administration guidance on the use of social media to promote pharmaceuticals shows that regulators understand the challenges of policing online comments while also making it clear that manufacturers will have to answer for remarks made on their behalf, attorneys say.
Here, lawyers provide four takeaways from the long-awaited document:
Set Boundaries for Company Agents
One potentially tricky section of the guidance said that drugmakers are responsible for comments made by their agents, such as paid speakers, but only...
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.